Recently, we demonstrated in a large European cohort that plasma concentrations of specific P-tau species (P-tau181 and P-tau231) are significantly higher in patients with DLB compared with healthy controls (HCs), but lower compared with AD.17 Furthermore, we found that plasma P-tau biomarkers are elevated in DLB participants with concordant amyloid copathology and are associated with cognitive decline in the whole DLB group. The gene discussed is MAPT; the disease is amyloidosis.